Enabling the discovery of vaccines and antiviral therapeutics against SARS-CoV-2, influenza, dengue, Zika, and other viruses

Reporter Viruses

Epitope Mapping

MAb Specificity Testing

Your job is to defeat COVID-19.
Our job is to help get you there.

Our industry-leading platforms help accelerate the development of your vaccines and therapeutics  

We are in this together

SARS-CoV-2 Reporter Viruses

fast neutralization data in your BSL-2 lab

SARS-CoV-2 Reporter Virus Particles (RVPs) are replication-incompetent pseudovirus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation

  • Safe in a BSL-2 environment
  • Neutralization titers strongly correlate with assays using live virus (learn more) 
  • Quantitative (luciferase) or fluorescent (GFP) read-out
  • Compatible with high-throughput plate-based assays
  • Quality-controlled reagents based on 20 years of manufacturing reporter viruses 

Our scientists are monitoring FDA guidances for COVID-19 vaccine and antibody development

SARS-CoV-2 variant RVPs can accelerate your discovery programs while meeting FDA recommendations (learn more) 

Reporter Viruses and Variant Strains

20 years of experience in virology and manufacturing pseudotyped Reporter Virus Particles
130+ virology publications on SARS-CoV-2, Ebola, Chikungunya, dengue, and more

Integral Molecular does not work with any live viruses capable of causing infectious disease. We have developed Reporter Virus Particles (RVPs) to enable scientists to study viral components without the risk of exposure to viruses or the spread of contagious illnesses.

“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”

-Yufei Xiang, University of Pittsburgh School of Medicine

Fast characterization data to progress your therapeutic antibodies

Epitope Mapping

  • Differentiate your antibody’s mechanism of action
  • Strengthen your antibody’s intellectual property 
  • Success rate of >95% and 4–8 week turnaround time for select MAbs*

*SARS-CoV-2, Zika and, dengue MAbs

Rapid Specificity Profiling

  • De-risk therapeutic antibody development by detecting off-target interactions
  • MAb screening on 6,000 membrane proteins in live cells
  • 4-week turnaround time


“MPA technology quickly provided us with the reassurance that Abound Bio’s potent, neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins which could be associated with toxicity.”

-John W. Mellors, MD, CEO, Abound Bio

 Published in Li et al., 2020, Cell

130+ Virology Publications

Featured Case Studies

SARS-CoV-2 RVPs and live virus show similar neutralization titers
Learn how the Membrane Proteome Array enabled AboundBio to rapidly progress a SARS-CoV-2 MAb

See how Merck categorized RSV F glycoprotein antibodies from existing therapeutics

Frequently Asked Questions

Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery and antibody discovery against viral targets.

RVPs incorporate virus-specific envelope proteins that are antigenically equivalent to those of live wild-type viruses. They contain a modified genome so they are safe and replication-incompetent.

RVPs are useful for high-throughput infectivity and neutralization assays. They are an efficient alternative to plaque assays.

Luciferase and GFP is used for quantitative read out.

Ready To Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.

Or call (215) 966-6061